Impact of Cytomegalovirus Infection on Severe Hepatitis C Recurrence in Patients Undergoing Liver Transplantation.

Transplantation

1 Unit of Infectious Diseases, Hospital General Universitario de Ciudad Real, Spain. 2 Spanish Network for the Research in Infectious Diseases (REIPIRD12/0015), Instituto de Salud Carlos III, Madrid, Spain. 3 Liver Unit-Internal Medicine Department, Centro de Investigación Biomédica en Red en el Área temática de Enfermedades Hepáticas y Digestivas, CIBERehd, Hospital Universitario Vall d'Hebron, Barcelona, Spain. 4 Liver Transplantation Unit, Hospital Clínico Universitario, Santiago de Compostela, Spain. 5 Liver Transplantation Unit, Hospital Universitario Virgen del Rocío, Seville, Spain. 6 Liver Transplantation Unit, Hospital Universitario Reina Sofía-IMIBIC-UCO, CIBERehd, Cordoba, Spain. 7 Unit of Infectious Diseases, Hospital Universitario 12 de Octubre, Madrid, Spain. 8 Liver Unit, Hospital Universitario Central de Asturias, Oviedo, Spain. 9 Unit of Liver Transplantation, Hospital Universitario de Bellvitge, Barcelona, Spain. 10 Liver Unit, Clínica Universitaria de Navarra, CIBERehd, Pamplona, Spain. 11 Liver Transplantation Unit, Hospital General Universitario Gregorio Marañón, Madrid, Spain. 12 Department of Digestive Diseases, Hospital Universitario Río Hortega, Valladolid, Spain. 13 Clinical Unit of Infectious Diseases, Hospital Universitario Reina Sofía-IMIBIC-UCO, Cordoba, Spain.

Published: March 2016

Background: The influence of cytomegalovirus (CMV) on recurrent hepatitis C virus (HCV) in liver grafts is controversial. Our aim was to investigate the association between CMV infection and disease and severe HCV recurrence (composite variable of presence of stage 3 to 4 fibrosis, need for retransplantation or death due to liver disease) in the first year after transplantation.

Methods: An observational, prospective, multicenter study was performed. The CMV replication was monitored by determining CMV viral load weekly during hospitalization after transplantation, twice monthly in the first 3 months after discharge, and at each follow-up visit until month 12. Liver fibrosis was assessed histologically by liver biopsy or transient elastometry. Pretransplant, intraoperative, and posttransplant variables were recorded. Multiple logistic regression was performed to study the impact of CMV on severe HCV recurrence.

Results: Ninety-eight patients were included. The CMV infection was detected in 48 patients (49%) in the first year posttransplant, of which 11 patients (22.9%) had CMV disease. Twenty-three patients (23.5%) had severe HCV recurrence. Of these, 17 (73.9%) developed stage 3 to 4 fibrosis, 4 (17.4%) died, and 2 (8.7%) underwent retransplantation. Only 7 of 12 (58.3%) seronegative recipients of a seropositive donor (positive donor/negative recipient [D+/R-]) received universal prophylaxis, and 10 of 12 (83.3%) D+/R- patients developed CMV replication. In the multivariate analysis, the presence of CMV D+/R- serodiscordance (odds ratio, 6.87; 95% confidence interval, 1.89-24.99; P = 0.003), and detection of a higher peak HCV viral load (odds ratio, 3.85; 95% confidence interval, 1.49-9.94; P = 0.005) were associated with severe HCV recurrence.

Conclusions: Our results support an association between CMV D+/R- serodiscordance and severe HCV recurrence in patients undergoing liver transplantation for HCV liver disease.

Download full-text PDF

Source
http://dx.doi.org/10.1097/TP.0000000000000912DOI Listing

Publication Analysis

Top Keywords

severe hcv
20
hcv recurrence
12
cmv
10
recurrence patients
8
patients undergoing
8
undergoing liver
8
liver transplantation
8
hcv
8
hcv liver
8
association cmv
8

Similar Publications

Hepatitis C virus (HCV) infection is a major global public health concern, particularly in hemodialysis (HD) patients. This study aims to evaluate the demographic, clinical, and laboratory characteristics of HCV-positive patients undergoing HD and assess the long-term impact of direct-acting antivirals (DAAs) on patient outcomes. Moreover, a narrative review aims to summarize the current knowledge regarding HCV treatment in HD patients.

View Article and Find Full Text PDF
Article Synopsis
  • Hepatitis C Virus (HCV) is a serious bloodborne virus causing liver disease, and currently, there are no effective vaccines to prevent its spread, highlighting the importance of understanding T cell epitopes (TCEs) in immune response.
  • TCellPredX is a new prediction tool designed to identify TCEs related to HCV by using advanced machine learning techniques and a variety of feature encodings, which together improve the predictive accuracy of TCE identification.
  • The tool has demonstrated high accuracy scores (0.900 and 0.897) in identifying relevant peptides for vaccine development, establishing TCellPredX as a significant resource for future research aimed at creating an effective HCV vaccine.
View Article and Find Full Text PDF

Lactoferrin (Lf) is a naturally occurring glycoprotein known for its antiviral and antibacterial properties and is present in various physiological fluids. Numerous studies have demonstrated its antiviral effectiveness against multiple viruses, such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), influenza virus (IFV), herpes simplex virus (HSV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). Lf, a vital component of the mucosal defense system, plays a crucial role in inhibiting viral infection by binding to both host cells and viral particles, such as the Hepatitis C virus (HCV).

View Article and Find Full Text PDF

Background And Objectives: Hepatitis B virus (HBV) and hepatitis C virus (HCV) are significant global health challenges, leading to severe complications such as liver cirrhosis and hepatocellular carcinoma. Despite available vaccines and treatments, these infections persist, particularly, in regions such as Iraq. This study aimed to assess the prevalence of HBV and HCV among couples attending premarital screening programs in Zakho, Kurdistan Region of Iraq and explore the associated demographic risk factors.

View Article and Find Full Text PDF

Host-targeting antivirals for chronic viral infections of the liver.

Antiviral Res

December 2024

Department of Molecular and Medical Virology, Ruhr University Bochum, Bochum, Germany; German Centre for Infection Research (DZIF), External Partner Site, Bochum, Germany. Electronic address:

Infection with one or several of the five known hepatitis viruses is a leading cause of liver disease and poses a high risk of developing hepatocellular carcinoma upon chronic infection. Chronicity is primarily caused by hepatitis B virus (HBV) and hepatitis C virus (HCV) and poses a significant health burden worldwide. Co-infection of chronic HBV infected patients with hepatitis D virus (HDV) is less common but is marked as the most severe form of chronic viral hepatitis.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!